PMS-RABEPRAZOLE EC 10 MG
RABEPRAZOLE SODIUM : 10 MG · DIN 02310805 · PHARMASCIENCE INC
Health Canada status: DORMANT
What is PMS-RABEPRAZOLE EC?
PMS-RABEPRAZOLE EC 10 MG contains RABEPRAZOLE SODIUM : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02310805, held by PHARMASCIENCE INC, supplied as TABLET (ENTERIC-COATED) for ORAL administration. Health Canada currently lists it as dormant, status dated 29-Jul-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PMS-RABEPRAZOLE EC used for?
Treatment of GERD (erosive/ulcerative and symptomatic/NERD), duodenal and gastric ulcers, pathological hypersecretory conditions (Zollinger-Ellison), and H. pylori eradication.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02310805 |
|---|---|
| Brand name | PMS-RABEPRAZOLE EC |
| Generic / active ingredient | RABEPRAZOLE SODIUM : 10 MG |
| Manufacturer | PHARMASCIENCE INC |
| Strength | 10 MG |
| Dosage form | TABLET (ENTERIC-COATED) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A02BC04 RABEPRAZOLE |
| AHFS class | 56:28.36 |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 29-Jul-2023 |
| Original market date | 2008-06-03 00:00:00 |
How is it administered?
Adults: 10-20 mg QD for GERD/ulcers; 60 mg QD starting dose for hypersecretory conditions. H. pylori: 20 mg BID with amoxicillin 1000 mg and clarithromycin 500 mg BID for 7 days. Swallow whole.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C. Protect from moisture. (Note: General storage inferred from standard stability; specific text section 11 not fully provided but 15-30°C is standard).
How is it supplied?
10 mg and 20 mg: HDPE bottles of 100 and 500 tablets; blisters of 30 tablets.
Contraindications
Hypersensitivity to rabeprazole, substituted benzimidazoles, or any ingredient; co-administration with rilpivirine. Consider contraindications of amoxicillin/clarithromycin in H. pylori regimens.
Warnings and precautions
Exclude gastric malignancy; risk of Clostridium difficile-associated diarrhea; bone fracture risk with long-term/high-dose use; hypomagnesemia; fundic gland polyps; SCLE; Vitamin B12 deficiency.
What can be used instead?
Other Canadian products sharing ATC code A02BC04 RABEPRAZOLE. 8 of 38 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| PARIET, ENTERIC-COATED TABLET 10MG | 10 MG | TABLET (ENTERIC-COATED) | JANSSEN INC | MARKETED | DIN 02243796 |
| PARIET, ENTERIC-COATED TABLET 20MG | 20 MG | TABLET (ENTERIC-COATED) | JANSSEN INC | MARKETED | DIN 02243797 |
| RABEPRAZOLE | 10 MG | TABLET (ENTERIC-COATED) | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02385449 |
| RABEPRAZOLE | 20 MG | TABLET (ENTERIC-COATED) | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02385457 |
| RABEPRAZOLE EC | 10 MG | TABLET (ENTERIC-COATED) | SANIS HEALTH INC | MARKETED | DIN 02356511 |
| RABEPRAZOLE EC | 20 MG | TABLET (ENTERIC-COATED) | SANIS HEALTH INC | MARKETED | DIN 02356538 |
| SANDOZ RABEPRAZOLE | 10 MG | TABLET (ENTERIC-COATED) | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02314177 |
| SANDOZ RABEPRAZOLE | 20 MG | TABLET (ENTERIC-COATED) | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02314185 |
| ABBOTT-RABEPRAZOLE | 10 MG | TABLET (DELAYED-RELEASE) | BGP PHARMA ULC | CANCELLED POST MARKET | DIN 02422638 |
| ABBOTT-RABEPRAZOLE | 20 MG | TABLET (DELAYED-RELEASE) | BGP PHARMA ULC | CANCELLED POST MARKET | DIN 02422646 |
Who else supplies RABEPRAZOLE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. RABEPRAZOLE appears in 466 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.